Content Type: Article

  • UK LLPs – Salaried Member Rules: HMRC issues revised guidance on Condition C

    UK LLPs – Salaried Member Rules: HMRC issues revised guidance on Condition C

    ARTICLE / CLIENT ALERT

    UK LLPs – Salaried Member Rules: HMRC issues revised guidance on Condition C

    April 17, 2025

    Read time: 8 min

    Key takeaways
    Overview

    HMRC has revised its guidance on the application of the targeted anti-avoidance rule (TAAR) to Condition C of the salaried member rules. The new guidance states that HMRC accepts that a “genuine contribution made by [an] individual to the LLP, intended to be enduring and giving rise to real risk” will not trigger the TAAR. The consequence of this change of view by HMRC should be that, in most cases, a “top-up” contribution to the LLP made by an individual in order to ensure that Condition C is failed – such that the individual is not a salaried member – will not be caught by the TAAR.

    In a recent Alert, we discussed the decision of the Court of Appeal in HMRC v BlueCrest Capital Management UK LLP on the interpretation of Condition B of the salaried member rules (the “significant influence” test). Given the difficulties and uncertainties created by that Court of Appeal decision for LLPs relying on Condition B, it is possible that there might be a renewal of interest amongst investment manager LLPs in relying on Condition C in their salaried member analysis. In this context, HMRC’s more sensible interpretation of Condition C – as set out in the revised guidance – is most welcome.

    Condition C and the TAAR

    Condition C is not met – such that an individual is not a salaried member – if the individual has made a capital contribution to the LLP and it is expected that this capital contribution will be 25 percent or more of the individual’s “disguised salary” for the relevant period. (By way of reminder, “disguised salary” is remuneration that is fixed or does not vary by reference to the overall profits of the LLP.)

    However, the salaried member rules also include a targeted anti-avoidance rule (TAAR) which states that no regard is to be had to any arrangements “…the main purpose, or one of the main purposes of which, is to secure that the individual…is not a salaried member”[1]

    HMRC Guidance

    In August 2024, HMRC (without warning) revised its published guidance to state that HMRC believed that an arrangement under which “…members increase their capital contributions periodically in response to their expected disguised salary, in order to avoid meeting Condition C…will trigger the TAAR…” and that “…no regard can be had to [an amount of capital contributed as part of such a “top-up arrangement”] when considering whether [a member] meets Condition C…”. By implication, this would, in HMRC’s view, be the case even though such a “top-up” contribution represented a genuine commercial arrangement between member and LLP and gave rise to real economic risk for the member.

    These changes caused significant concern amongst LLPs and their members that HMRC had changed its approach, and would now invoke the TAAR to treat members as salaried members in cases where members had (in reliance on HMRC’s pre-revision guidance) made periodic “top-up” contributions in order to fail the minimum 25 percent of “disguised salary” requirement of Condition C.

    In response to these concerns, HMRC has now revised its guidance a second time in an attempt to clarify when it will seek to apply the TAAR in the context of Condition C.

    HMRC Guidance – the Latest Changes

    The latest guidance sets out a more sensible approach to the application of the TAAR in the context of Condition C, and effectively disregards the potentially TAAR-triggering purpose in certain circumstances. The guidance now confirms that HMRC accepts that “…a genuine contribution made by the individual to the LLP, intended to be enduring and giving rise to real risk, will not trigger the TAAR…”.

    The revised guidance suggests that we should look to “the ordinary meaning of [the] words” in interpreting this phrase, and that “all the facts and circumstances should be taken into account”. More helpfully, it goes on to state that “real risk refers to whether the individual is personally at actual risk of losing the contribution…in the event that the LLP makes a loss or becomes insolvent, rather than whether the LLP itself is really at risk of making a loss. The fact that an LLP is well capitalised, such that practical risk of insolvency is very low, would not mean that the contribution is not at real risk.”

    HMRC’s guidance thus now addresses the important question of what an LLP is required to do with a capital contribution for that capital contribution to be considered “enduring and intended to be genuine and at real risk”. It confirms that HMRC would not consider that a contribution was not genuine or at real risk “…if the LLP did not require additional capital before it was made…” and that “HMRC recognises that LLPs may put contributions to a variety of uses…” The guidance then goes on “But if the contribution is not intended to provide funding which is available for use by the LLP, for example because it is ringfenced for the benefit of the member(s) or the reality is that the money makes its way back to the member(s) as part of a circular arrangement, that would indicate it is not a genuine contribution or at real risk.”

    The revised guidance should therefore now alleviate concerns over the application of the TAAR to Condition C in a common scenario in the asset management sector. This is where an LLP has no requirement for additional capital for its ordinary business purposes, but members of the LLP nonetheless make capital contributions to the LLP in order to ensure that the Condition C requirement is met. In this case, the LLP is likely to invest this surplus capital, either in the funds which it manages or in other investments. But a capital contributions used in this way, provided that it is not “ringfenced for the benefit of the member(s)” – as distinct from the LLP itself – and does not “make its way back to the member(s) as part of a circular arrangement”, should, on the terms of the revised guidance, still be regarded as “enduring and intended to be genuine and at real risk”, notwithstanding that it is surplus capital to the LLP which is invested by the LLP for the benefit of the LLP.[2]

    HMRC’s guidance in relation to what counts as a capital contribution in the first place has not changed. Nonetheless it is worth revisiting here. Thus it remains clear that, in HMRC’s view, if a member makes a capital contribution but is or may in certain circumstances be entitled to withdraw an amount of that capital without ceasing to be a member of the LLP – say, where a member may be entitled to withdraw an amount of their capital contribution if the LLP reaches a certain level of profitability – that amount which is potentially refundable does not count as part of the capital contribution for purposes of Condition C. Similarly, if a member is or may be entitled to require someone else to reimburse them for a part of their capital contribution in certain circumstances, or if they are insured for the loss of their capital contribution, then this amount does not count as part of their capital contribution. As acknowledged above, this has always been part of HMRC’s guidance, but it would be easy to overlook this when considering the terms upon which members make capital contributions to the LLP and the impact of setting out potential circumstances in which they might be entitled to a return of their contributed capital.

    Conclusion

    This more sensible approach to the TAAR in the context of Condition C now set out in HMRC’s revised guidance is clearly welcome. It is also in line with the guidance generally understood to apply prior to the changes made by HMRC in August 2024, albeit with the TAAR as it potentially applies to Condition C having been substantially de-fanged.

    Perhaps what we should take away from this to-and-fro over HMRC’s guidance on Condition C, and the back-and-forth in the courts over the meaning of “significant influence” in Condition B, is the fundamental importance of an LLP thinking in-depth about its approach to the salaried member rules, and the Condition(s) it is seeking to rely on, and then carefully documenting that analysis and the basis for its conclusions. Without that as a minimum, it is very possible that an LLP could be caught up in the shifting sands of the salaried member rules.

    If you would like to discuss any aspect of the salaried members rules as they apply in your particular circumstances, please contact Dan Roman, Nick Fagge or your usual Schulte contact.


    [1]The TAAR is relevant to each of the three conditions of the salaried member rules (including Condition B as considered in the recent BlueCrest decision). However, we are concerned here only with its application to Condition C.

    [2] However, we also note the potential risk of total reliance on HMRC guidance in light of the recent BlueCrest case.


    This communication is issued by Schulte Roth & Zabel International LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2025 Schulte Roth & Zabel International LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Nick Fagge

    Partner

    London – One Eagle Place

    More insights

  • Beyond Private Equity Transaction Oversight: Mass. H.5159 Includes New Licensing Requirements

    Beyond Private Equity Transaction Oversight: Mass. H.5159 Includes New Licensing Requirements

    ARTICLE / CLIENT ALERT

    Beyond Private Equity Transaction Oversight: Mass. H.5159 Includes New Licensing Requirements

    April 16, 2025

    Read time: 12 min

    Key takeaways
    Overview

    H.5159, An Act Enhancing the Market Review Process, was signed into law in January 2025. The primary focus of H.5159 is to expand the Commonwealth’s healthcare oversight mechanisms, particularly with respect to private equity transactions. Read the following client alert for a comprehensive summary of those changes: “Massachusetts H.5159 Seeks to Reshape Private Equity in Healthcare.” This article focuses on other H.5159 regulatory updates that amend M.G.L. c. 111. Specifically, H.5159 creates licensing regimes for office-based surgical centers and urgent care centers and expands Department of Public Health (DPH) oversight for licensed hospitals.

    This client alert also summarizes the Massachusetts Health Policy Commission’s (HPC’s) March 17, 2025, advance guidance for providers and provider organizations proposing to make material changes to their operations or governance structures between the legislation’s effective date of April 8, 2025, and the date that the updated regulations for the Material Change Notice process are available.

    In depth

    Regulation of DPH Licensed Facilities

    Under M.G.L. c. 111, DPH has the authority to license, regulate, and supervise certain healthcare facilities. Historically, these facilities included only hospitals, ambulatory surgical centers (ASCs), clinics, labs, and long-term care facilities. H.5159 authorizes DPH to regulate two new licensed facility types: office-based surgical centers and urgent care centers. It directs DPH to establish rules, regulations, and practice standards for these new licensure types by October 1, 2025.  H.5159 also expands DPH’s regulatory authority over acute care hospitals, specifically with regard to closures and real estate transactions. These changes signal the Commonwealth’s continued interest in regulating the provision of healthcare and maintaining oversight of quality, safety, and access.

    New License Categories

    As detailed further below, H.5159 outlines general licensure requirements, applicable to both office-based surgical centers and urgent care centers, and other provisions specific to each licensure type, including the procedures and services that can be provided at office-based surgical centers and at urgent care centers, respectively. H.5159’s description of the services and procedures that trigger the need for licensure is somewhat ambiguous, and there is potential for overlap with DPH’s existing licensure types (e.g., procedures that could be performed at either an ASC or an office-based surgical center), which, for example, may present an opportunity for providers performing in-office surgeries to seek licensure under a potentially less rigorous licensure scheme than DPH clinic licensure for ASCs.

    Some physician practices have historically performed certain activities in an office setting that were exempt from facility licensure and should carefully assess their activities under these two new regimes to identify whether licensure is required.

    Office-Based Surgical Centers

    H.5159 includes an exemption from licensure for facilities that perform procedures that fall within the statutory definition of “office-based surgical services” but are otherwise licensed by DPH as hospitals, ASCs (licensed by DPH as clinics), or abortion clinics, under M.G.L. Ch. 122, § 12M. This exception for existing licensure indicates the Commonwealth’s intention to use the office-based surgical center license type to regulate a subset of moderately complex procedures, and to distinguish such procedures from those which must be performed at ASCs or hospitals.

    Based on the definitions of “office-based surgical procedures” and “surgical services” in the ASC context, the Commonwealth is focused on the level of sedation administered in connection with the procedure. The sedation levels indicated in the “office-based surgical procedures” definition are slightly more precise than in the “surgical service” definition; however, certain overlapping elements of the definitions (e.g., general anesthesia appears in both definitions) create haziness as to which licensure type is appropriate.

    • “Office-based surgical procedures” means procedures requiring general anesthesia, moderate sedation, or deep sedation. It includes all liposuction procedures, and excludes minor procedures and procedures requiring minimal sedation.
    • “Surgical service” means providing diagnosis or care through endoscopic procedures or operative procedures requiring regional or general anesthesia (105 CMR 140.020).

    The fact that office-based surgical procedures expressly include liposuction procedures regardless of sedation levels suggests that the new licensing scheme may be aimed at cosmetic surgery providers, whereas the ASC regulations specifically point to endoscopic procedures. DPH regulations and corresponding guidance likely will clarify the applicability of these licensure types.

    DPH’s determination as to which procedures require office-based surgical center licensure will have implications for providers who perform in-office surgical procedures and have historically relied on the physician office exemption from DPH clinic licensure to do so.

    The Massachusetts Medical Society (MMS) Office-Based Surgery Guidelines, which have been endorsed by the Massachusetts Board of Registration in Medicine, may provide insight into the practice standards that DPH will implement in regulations (e.g., transfer planning, professional supervision requirements, reporting of adverse events) and be a helpful reference for physician offices operating under a clinic licensure exemption. While these guidelines do not address specific procedures or types of procedures, they categorize office-based surgery into levels, primarily based on the sedation administered. The H.5159 definition of “office-based surgical procedures” appears to most closely align with MMS Level III Office Surgery, which includes procedures requiring use of deep sedation, general anesthesia, or analgesia.

    Without DPH regulations and guidance on the new licensure type, it is unclear the extent to which physician office exemptions for office-based surgery will continue to exist; however, based on the definition of “office-based surgical procedures,” it seems clear that “minor procedures and procedures requiring minimal sedation” will fall outside the scope of licensure.

    Physician offices performing office-based surgeries and new providers looking to enter the Massachusetts market should review H.5159 to determine if the services they provide may fall within the scope of licensure as an office-based surgical center.

    Urgent Care Centers

    H.5159 defines an urgent care center as a clinic owned and operated by an entity, that is unaffiliated with a licensed hospital and provides in-office urgent care services. “Urgent care services” are defined as a model of care for the diagnosis, treatment, management, or monitoring of acute or chronic disease or injury that includes each of the following elements:

    • Intended to treat illness or injury that is immediate in nature but does not require emergency services;
    • Provided on a walk-in basis without prior appointment;
    • Available to the public during days and times when primary care provider offices are not customarily open; and
    • Not intended to and should not replace preventative or routine care.

    Based on this definition of urgent care center, the Commonwealth is concentrated on regulating entities that provide convenient and nonemergent care services. To avoid capturing physician offices that may provide simply “convenient after-hours care,” the law requires that all definitional elements of “urgent care services” be satisfied. H.5159 also intentionally limits the definition of “urgent care center” to facilities “owned and operated by an entity,” creating an implied exception to licensure for any physician practices owned and operated by one or more individual practitioners who provide urgent care services. Such an exemption is similar to that already existing inside the licensed clinic schema, as physician practices wholly owned or controlled by one or more practitioners have historically avoided regulation by DPH as “clinics” (M.G.L. c. 111 § 52). This intentional limitation further indicates the Commonwealth’s desire not to capture sole practitioners or group practices that may provide after-hours, walk-in care for their patients as a convenience, even though the services may otherwise fall into the definition of “urgent care services.”

    In addition to the individual exemption, H.5159 expressly provides that urgent care centers do not include DPH-licensed hospitals, clinics, limited services clinics, or federally funded community health centers as defined by 42 U.S.C. 254b. Historically, given the lack of an established and tailored licensing regime, some urgent care centers have fallen under “clinic” licensure. Given the express exemption, these already-licensed facilities will not need to apply for additional or different licensure. With respect to office-based surgery, the exception for existing licensure indicates the Commonwealth’s intention to use the licensing of urgent care centers to regulate a subset of convenient care that has previously gone unregulated and to distinguish the nature of urgent care centers from other licensed facilities by focusing on lack of appointment structure and rigid business hours, rather than service-type as with office-based surgery.

    New entrants into the urgent care market should closely review the H.5159 definitions described above and, when promulgated by DPH, the regulations governing urgent care centers to determine whether they may qualify as a DPH urgent care facility or licensed clinic, or whether they fall outside of the DPH license requirements altogether. Existing unlicensed facilities owned and operated by entities that provide care for nonemergent diseases or injuries on a walk-in basis outside standard business hours should similarly review these new rules to determine whether they will be subject to DPH regulation for the first time.

    Requirements Applicable to Both Licensure Types

    In promulgating the new regulations, DPH has the express discretion to include regulations that are currently applicable to ASCs (which are currently licensed as clinics and require a Determination of Need). DPH also has the authority to grant a one-time provisional license to a licensee that holds accreditation from certain specified accrediting bodies, is deemed to be in substantial compliance with the initial DPH regulations, and demonstrates potential for achieving full compliance within the provisional licensure period. Any person or entity that operates an office-based surgical center or urgent care center without obtaining licensure will face fines and other discipline.

    The new license categories will also require that certain incidents (e.g., healthcare-associated infections, serious reportable events, serious adverse drug events, and financial delinquency, including repossession of medical equipment or supplies) be reported to DPH. Contract terms between these licensees and vendors that permit the repossession of medical or surgical equipment without prior notice to DPH are banned and considered void as against public policy.

    Expansion of DPH Oversight Over Acute Care Hospitals; Prohibition Leasing of Main Campus from a REIT

    H.5159 prohibits DPH from issuing or renewing an acute care hospital license if the main campus of the hospital is leased from an REIT. “Main campus” means the licensed premises within which the majority of inpatient beds are located. However, an exemption exists for any acute care hospital that leases its main campus from an REIT as of April 1, 2024. An exempt acute care hospital will maintain its exempt status after a transfer as long as the transferee otherwise satisfies all other requirements for licensure.

    H.5159 also expands DPH’s oversight authority over the lifecycle of acute care hospitals in Massachusetts. DPH is prohibited from issuing an initial or renewal license to establish or maintain an acute care hospital unless the applicant is in compliance with the reporting requirements of the Center for Health Information and Analysis (CHIA). Before the closure of an acute care hospital or any essential service, DPH must seek an HPC impact analysis of the closure on the community. The law also requires DPH to hold a public hearing on the closure of the given hospital or essential service.

    Advance Guidance for Providers and Provider Organizations Undergoing a Material Change

    In anticipation of the amendments to M.G.L. c. 6D, § 13 that took effect on April 8, 2025, the HPC issued a bulletin providing advance guidance to providers and provider organizations proposing to make a material change to their operations or governance structure, and published an updated form for reporting the material change. Below is a summary of the key points from the advance guidance, including the definition of “material change,” information requests to significant equity investors, and the updated notice of material change filing form. Apart from this advance guidance, existing regulations pertaining to the Notices of Material Change and Cost and Market Impact Reviews (958 CMR 7.00) will remain in effect until the HPC promulgates new regulations, which is expected to occur in the summer or fall of 2025.

    Definition of “Material Change”

    The amendment outlined four new types of material change that trigger the notice requirement, and HPC provided definitions for three out of those four, as follows:

    • “Significant expansions in a Provider or Provider Organization’s capacity” include any increase to a provider or provider organization’s capacity that requires a DON Application for Substantial Capital Expenditure (as defined in 105 CMR 100).
    • “Transactions involving a significant equity investor which result in a change of ownership or control of a Provider or Provider Organization” include any investment by an equity investor that will change the ownership of a provider or provider organization, and any investment in excess of $10 million that results in an equity investor having significant control over a provider or provider organization, such as the potential to appoint a board members or make key business decisions (e.g., hiring or terminating staff).
    • “Significant acquisitions, sales, or transfer of assets including, but not limited to, real estate sale lease-back arrangements” include the sale of any licensed facility or the sale of real property assets where healthcare services are delivered for the purposes of a real estate lease-back arrangement.

    The fourth type of material change involves the conversion of a provider or provider organization from a nonprofit entity to a for-profit entity, which the HPC has not further defined at this time. Existing law already outlines a process for attorney general review of conversion of nonprofit hospitals, as outlined in M.G.L. c. 180 § 8A. Written notice must be provided at least 90 days prior to the effective date of the proposed conversion and may be followed by a public hearing. In its review of each transaction, the attorney general must:

    • Confirm that the proposed transaction complies with applicable nonprofit and charities law;
    • Review transactional details;
    • Conduct a fair market value analysis;
    • Review conflicts of interests;
    • Confirm that the proposed transaction is in the public interest;
    • Determine charitable asset uses; and
    • Engage an independent healthcare access analyst if needed.

    The law also outlines the process for the sale of charitable assets, so any nonprofit entities undergoing this type of transaction should be prepared to navigate both processes.

    Information Requests to Significant Equity Investors

    Effective April 8, 2025, the HPC is authorized to request information from significant equity investors and other parties involved in a transaction. This information may include details about the investor’s capital structure, general financial condition, ownership and management structure, and audited financial statements. While this information does not need to be submitted publicly as part of the Material Change Notice form, it may be requested confidentially during the HPC’s review process. The HPC will maintain the confidentiality of all nonpublic information and documents obtained in connection with a Material Change Notice or CMIR, as requested by the parties.

    Authors

    Sarah Kitchell

    Partner

    Boston

    Callee Donovan

    Associate

    Boston

    Sarah Reis

    Associate

    Boston

    Lauren B. Flynn

    Associate

    Boston

    More insights

  • CMS Poised for Medicare, Medicaid Program Integrity Enforcement Actions

    CMS Poised for Medicare, Medicaid Program Integrity Enforcement Actions

    CLIENT ALERT / US POLICY

    CMS Poised for Medicare, Medicaid Program Integrity Enforcement Actions

    April 15, 2025

    Read time: 7 min

    Key takeaways
    Overview

    The Trump administration and 119th Congress are preparing to reduce federal expenditures by targeting Medicare and Medicaid fraud, waste, and abuse. Medicare enrollment revocations, Medicaid enrollment terminations, and extrapolated overpayments resulting from program integrity concerns can have devastating effects on providers. Providers and investors should be aware of preventative measures and appeal strategies to mitigate the anticipated increase in provider enrollment actions and reimbursement audits in the coming months and years.

    In depth

    Background

    The US Department of Health and Human Services estimates that Medicare overpaid fee-for-service providers $32 billion and Medicaid overpaid providers $31 billion in 2024. Only a fraction of these estimated improper payments were recovered, and these estimates do not include all fraudulently received payments. Between October 2020 and September 2023, the Centers for Medicare & Medicaid Services (CMS) revoked the Medicare billing privileges of almost 8,500 providers, preventing them from participating in the Medicare program for one to 10 years. Medicare revocations often cause providers to be added to the “preclusion list,” which prevents them from receiving payment from Medicare Advantage plans or writing prescriptions for Part D reimbursable drugs. If a provider is revoked from Medicare, the provider must be revoked from all state Medicaid programs. A Medicare revocation may prevent the provider from being involved in any item or service reimbursed by Medicare or Medicaid.

    In fiscal year 2023 alone, more than 2,500 providers were terminated from state Medicaid programs. Termination from one state Medicaid program requires the provider to be terminated from all other state Medicaid programs and may lead to Medicare revocation.

    Owners, directors, officers, and managing employees of Medicare and Medicaid providers that are revoked from Medicare or terminated from Medicaid also may be subject to enforcement scrutiny because of their affiliation with the revoked or terminated provider. CMS uses extensive provider ownership and control reporting obligations to identify common ownership or control of providers subject to enforcement action.

    Signs of Advances in Program Integrity

    Reporter: “Can you guarantee that Medicare, Medicaid, Social Security will not be touched?”

    President Trump: “I have said it so many times . . . We’re not going to touch it. Now, we are going to look for fraud.”

    Cabinet Meeting, February 26, 2025

    “The President said over and over and over, ‘We’re not going to touch Social Security, Medicare or Medicaid.’ We’ve made the same commitment. Now, that said, what we are going to do is go into those programs and carve out the fraud, waste and abuse, and find efficiencies.”

    US House of Representatives Speaker Mike Johnson, February 26, 2025

    Under some metrics, Medicare and Medicaid program integrity audits are a highly cost-effective strategy to reduce federal healthcare program expenditures. For example, prior reports have found that certain hospital admission audits have returned $24 – $29 to the Medicare trust fund for every $1 spent on audits.

    The apparent cost effectiveness of program integrity audits can be amplified in cases where CMS alleges that a high level of payment error exists at the provider. In these cases, CMS can evaluate a small sample of the provider’s claims to determine whether any claims were arguably improperly paid, and if so, multiply (or “extrapolate”) CMS’ alleged “error rate” from the sample across the entire universe of that provider’s claims for a defined time period. Through extrapolation, CMS can turn an alleged overpayment of thousands of dollars into multiple millions of dollars. CMS’s decision to extrapolate is generally not appealable.

    The CMS Center for Program Integrity conducts payment and compliance audits through contractors, including the Unified Program Integrity Contractors and the Recovery Audit Contractors. The Medicare Administrative Contractors (MACs) conduct “targeted probe and educate” audits focused on identifying overpayments and implement enrollment revocations. CMS contractors are private companies, their staff are not federal employees, and CMS selects the contractors through a competitive request for proposal process. All of these features, in addition to the cost-effective nature of auditing activities and accessibility of overpayment extrapolation, make the contractors an ideologically aligned mechanism for the Trump administration to reduce federal healthcare program expenditures by reducing fraud, waste, and abuse without cutting specific benefits or entitlements.

    Program Integrity Audit Response

    Robust compliance programs are the foundation for preventing and defending potential Medicare or Medicaid program integrity audits. Compliance programs should ensure that all claims submitted to third-party payors meet coverage requirements and are properly billed consistent with payor instructions. Internal and external auditing and monitoring of high-risk areas can prevent providers from engaging in anomalous billing practices that trigger an audit and can ensure the provider has sufficient medical record documentation to produce to an auditor. Auditing and monitoring for compliance with enrollment requirements are effective ways to prevent a potential enrollment revocation or termination.

    Once a reimbursement audit begins, it is critical to work with experienced legal counsel to ensure that the appropriate provider documentation is reviewed and produced to the auditor and that any appropriate explanations or supplemental information are provided. Legal counsel should assist with strategies to ensure that the provider is best positioned for success based on applicable legal standards and interpretations. The documentation and communications exchanged with the auditor should deescalate the audit and form the basis for any subsequent administrative appeal.

    If the audit results in a material finding that the provider believes was in error, it is important to appeal the finding and prevent cascading audits from other federal healthcare programs. Often, audits begin with a relatively small, low-value “probe” sample. If the probe sample reveals a high error rate that is not overturned, the provider is likely to be subject to further scrutiny and audits that may include a statistically valid sample and extrapolation. Sustained high error rates through appeal may require significant changes to the provider’s service offerings, revisions to documentation processes, and dedicated resources to support the services on a go-forward basis.

    For all of these reasons, strong advocacy during a program integrity audit and administrative appeal of adverse enrollment actions or overpayments is key to ensuring the continuity of medically necessary services for federal healthcare program beneficiaries and participants.

    Takeaways

    • Medicare and Medicaid program integrity audits, extrapolated overpayments, and enrollment actions may significantly increase under the current administration.
    • Program integrity reimbursement audits often begin with a low-value “probe” sample that progresses into a much larger statistically valid sample and extrapolated overpayment.
    • Providers that do not successfully overturn overpayment findings on appeal may be required to review historic claims for overpayments and change their operations, documentation, or billing on a go-forward basis, adversely affecting revenue for the item or service line.
    • Significant overpayment findings and enrollment enforcement actions at one provider may generate scrutiny for others, including providers with common ownership or control.
    • Investors should closely review active program integrity audits to understand potential risk exposure (direct and indirect) and how that exposure may be mitigated by qualified legal counsel.
    • Investors considering investing in a provider subject to Medicare or Medicaid audits should incorporate transaction terms that consider the potential exposure associated with potential enforcement actions and operational impacts.
    Authors

    Steven J. Schnelle

    Partner

    New York – One Vanderbilt Avenue

    Monica Wallace

    Partner

    Chicago

    Abygail Hoey

    Associate

    New York – One Vanderbilt Avenue

    More insights

  • Antitrust Under Trump: April 2025 Updates

    Antitrust Under Trump: April 2025 Updates

    ARTICLE / CLIENT ALERT / US POLICY

    Antitrust Under Trump: April 2025 Updates

    April 15, 2025

    Read time: 8 min

    Key takeaways
    Overview

    As the Trump administration’s antitrust landscape continues to develop, companies should stay alert to key changes in merger filing requirements, remedy expectations, agency personnel, and more. Signs indicate we are entering a less-hostile merger environment and enforcement may be more pragmatic, but there may also be more scrutiny of transactions involving certain industries or with the potential to impact competition to hire workers.

    Early engagement with counsel and thoughtful preparation of filings and remedy proposals will be crucial to navigating this evolving environment. Below is a high-level review of recent developments that could impact business strategy, dealmaking, and compliance.

    In depth

    Agency Personnel Shifts

    Mark Meador Approved as FTC Commissioner

    • On April 10, the US Senate confirmed the nomination of Mark Meador as a commissioner of the Federal Trade Commission (FTC), with a vote of 50-46.

    Former FTC Commissioners Challenge Terminations, Face Implications of DC Circuit Decision

    • Former Commissioners Alvaro Bedoya and Rebecca Slaughter filed complaints in the US District Court for the District of Columbia contesting their removal, relying on the US Supreme Court’s 1935 precedent in Humphrey’s Executor that protects “independent” regulatory agency leadership from presidential removal power.
    • In a 2-1 vote, the US Court of Appeals for the District of Columbia Circuit allowed similar agency-related terminations of agency officials from the National Labor Relations Board and Merit Systems Protection Board.
    • The majority stated that the agencies currently perform executive functions that the FTC did not at the time of Humphrey’s Executor and, therefore, officials may be lawfully removed by the president under his executive power. The decision outlines a relevant question for Bedoya’s and Slaughter’s cases: whether the 2025 FTC performs executive functions unlike the 1935 FTC.

    Policy Priorities

    New DOJ Partial to Populist Antitrust

    • When asked about the Trump administration’s “America First” movement as it applies to antitrust, Assistant Attorney General Gail Slater indicated that the Antitrust Division of the Department of Justice (DOJ) would work to further the goals of the movement, including its focus on protecting average households and workers.
    • The DOJ’s Principal Deputy Assistant Attorney General for Antitrust Roger Alford said the movement focuses on the concerns of the average American citizen and the industries in which they are actually spending their money, implying that those industries are a top priority for the Antitrust Division.
    • Alford explained that America First industries of focus include housing, healthcare, insurance, transportation, food and groceries, and entertainment.

    FTC Remains Concerned with Roll-Ups, Not Necessarily From Private Equity

    • Jordan Andrew, deputy assistant director of the FTC’s Mergers I Division, said that he would be surprised if the agency only focused on private equity firms when looking at industry roll-ups and that he believed the agency would use every tool in its statutory toolkit to pursue cases against roll-ups.

    DOJ Hosts Roundtables on Labor and Entertainment

    • Assistant Attorney General Slater met with members of Teamsters unions on April 4 to discuss their personal experiences with non-compete agreements, no-poach agreements, and other unfair labor practices they have encountered.
    • On the same day, Slater met with advocates, policymakers, and market participants in the music industry to discuss anticompetitive conduct in the entertainment industry, indicating that the DOJ will likely continue to look closely at this industry and pursue its suit against Live Nation.

    HSR Updates

    Agencies May Consider Revisions to HSR Rules

    • The FTC and DOJ are open to considering changing the new Hart-Scott-Rodino (HSR) filing rules created by the previous administration, according to FTC Chair Andrew Ferguson.
    • The agency heads may consider reforms to the rules if the information submitted by companies under the new rules is not useful to the agencies when reviewing transactions or if experience demonstrates that compliance is unjustifiably burdensome.

    FTC Says More-Detailed HSR Form Can Prevent Second Requests

    • David Shaw, principal deputy director of the Bureau of Competition, said that the granular information requested by the new HSR form can allow enforcers to evaluate a deal quickly and to move on when there are no anticompetitive concerns.
    • Shaw explained that the information required in the new form is information the FTC sometimes would not receive until late in the initial 30-day HSR waiting period in filings made under the old form, and he stated that getting the information on day one allows the FTC to act more confidently.
    • Shaw said that the Trump administration is looking for “off ramps at every step in the [HSR] process,” and indicated that parties should request early termination so that the FTC can move on when a deal raises no concerns.

    Merger Remedies

    DOJ Further Clarifies That Remedies Are One of Its Enforcement Tools, Calls for Remedy Proposals to Be Provided Alongside HSR Filings Where Appropriate

    • DOJ Deputy Director of Civil Enforcement George Nierlich recommends that parties propose remedies when they file their HSR form in order to shorten the review period for transactions that raise competitive concerns.
    • Nierlich advises that parties turn to the “fix-it first” approach in order to save time when they are aware of areas of potential concern and explains that the DOJ will review such remedy proposals in terms of whether they will succeed and ultimately fix the competitive concern.

    DOJ Avoids Chilling Dealmaking

    • Roger Alford has suggested that the Antitrust Division should avoid creating bottlenecks in the merger review process by bringing complaints unless the deals are “perfectly clean,” arguing that such an approach will ultimately chill dealmaking.
    • Alford further advises parties to present deals that are as clean as possible and to bring forward proposals to resolve competitive issues, indicating that the DOJ is open to negotiating remedies if there are issues that can be resolved through a consent order.

    Merging Parties Should Prove Fix Will Work, Says FTC

    • Albert Teng, counsel to the director of the Bureau of Competition at the FTC, explained that because merging parties have greater information than the antitrust agencies around a proposed remedy and a unique knowledge of the market and competitors, they should bear the burden of proving that a proposed remedy will work.
    • Teng further argued that because divestiture buyers may find an acquisition profitable, even if the business does not thrive, and because the risk of the remedy failing will be felt predominately by the public, they should bear the burden to demonstrate the remedy will be successful and preserve competition.
    • These statements are in line with those from administrations that preceded President Biden.

    FTC Open to Private Equity Divestiture Buyers

    • During the American Bar Association 2025 Antitrust Law Section Spring Meeting, agency personnel noted that, although the FTC will evaluate each situation on a case-by-case basis, the agency is not ideologically opposed to considering private equity firms as divestiture buyers and would consider them valid options in a divestiture.
    • Biden-era regulators expressed concern about the competitive ability of businesses divested to private equity, but the current administration does not appear to share the same reservations regarding private equity.

    Other Developments

    President Trump’s Economic Golden Age Requires Cutting Red Tape

    • President Trump signed an executive order on April 9 requiring federal agencies to consult with FTC Chair Ferguson and US Attorney General Pam Bondi to identify and eliminate statutes and regulations that reduce competition, entrepreneurship, and innovation, or create monopolies or barriers to new market entry.
    • In response, the FTC has launched a public inquiry into the impact of federal regulations that may be considered barriers to competition and to the American economy. Members of the public, such as workers, consumers, investors, and businesses, are encouraged to identify regulations with an anticompetitive effect.
    • This order came soon after the DOJ launched an Anticompetitive Regulations Task Force on March 27, which will similarly focus on getting rid of burdensome state and federal laws and regulations that limit competition and economic growth.
    • Assistant Attorney General Slater and the DOJ stated that the task force will seek to eliminate unnecessary barriers to competition, reduce compliance costs, and promote opportunities for small businesses and American families.

    As the Trump administration’s approach to antitrust takes shape through political appointments, policy statements, speeches, and enforcement actions, McDermott’s antitrust team continues to track new developments. We are providing important updates on issues pertinent to clients. Stay tuned for more at-a-glance reviews of relevant policy as it is being created.

    View our earlier insights on antitrust under the Trump administration.

    Authors

    Jon B. Dubrow

    Partner

    Washington, DC

    Michelle Lowery

    Partner

    Los Angeles, Chicago

    Megan C. Ingram

    Associate

    Washington, DC

    More insights

  • CMS Updates SNF Attachment Guidance Ahead of August 1 Enrollment Deadline

    CMS Updates SNF Attachment Guidance Ahead of August 1 Enrollment Deadline

    ARTICLE / CLIENT ALERT

    CMS Updates SNF Attachment Guidance Ahead of August 1 Enrollment Deadline

    April 14, 2025

    Read time: 9 min

    Key takeaways
    Overview

    Update: CMS has indefinitely suspended the CMS-855A SNF Attachment deadline. Read more about the suspension here.

    Skilled nursing facilities (SNFs) historically have been required to disclose ownership and managerial control information as part of their Medicare enrollment. However, these requirements were significantly expanded to require disclosure of information from additional disclosable parties (ADPs) who provide certain services to or exercise certain controls over SNFs. Both SNFs and ADPs should understand these new disclosure requirements and prepare accordingly ahead of the CMS-855A SNF Attachment deadline, which is now August 1, 2025.

    In depth

    Regulatory Background

    On November 17, 2023, the Centers for Medicare & Medicaid Services (CMS) published the final rule, Medicare and Medicaid Programs; Disclosures of Ownership and Additional Disclosable Parties Information for Skilled Nursing Facilities and Nursing Facilities; Medicare Providers’ and Suppliers’ Disclosure of Private Equity Companies and Real Estate Investment Trusts (See 88 FR 80141) (the Final Rule). The Final Rule implements portions of the Affordable Care Act that require SNFs to disclose ownership, managerial, control, and other information as part of their Medicare enrollment, including information on ADPs.

    To implement the Final Rule, CMS issued an updated CMS-855A SNF Attachment on October 1, 2024. In November 2024, CMS issued a subregulatory guidance document that further clarifies the new disclosure requirements. This document has been updated over time, as recently as April 9, 2025. The updated CMS-855A SNF Attachment must be completed by all SNFs by August 1, 2025.

    What Is an ADP?

    CMS defines an ADP as any person or entity who:

    • Exercises operational, financial, or managerial control over the SNF or a part thereof, or provides policies or procedures for any of the SNF’s operations or provides financial or cash management services to the SNF
    • Leases or subleases real property to the SNF or owns a whole or part interest equal to or exceeding 5% of the total value of such real property
    • Provides management or administrative services, management or clinical consulting services, or accounting or financial services to the facility.

    This definition is intentionally broad and encompasses a wide variety of service providers. Further, an entity or person is considered an ADP based on the services they provide, rather than their title or professional status. CMS has provided a non-exhaustive list of examples, detailed below.

    Financial Control and Cash Management Services

    • Accounting: Includes any accounting services, including tax preparation and preparation of cost reports.
    • Financial Control: Includes monitoring or managing the SNF’s finances, holding authority to approve the expenditure of SNF funds, an owning organization of the SNF that funds part of the SNF’s operations, and banks that have given the SNF a line of credit.
    • Financial Services: Includes investment banking, investment management, asset management, financial advice, accounting, financial audits, and other services for the SNF.
    • Cash Management Services: Includes advising on cash flow and other financial matters and handling the SNF’s financial transactions, such as automated clearing house payments and mobile banking.

    Clinical and Compliance Services

    • Clinical Consulting: Assessing or advising on how to improve or modify any aspect of the SNF’s provision of healthcare.
    • Policies and Procedures: Developing or furnishing guidelines regarding the execution of any aspect of the SNF’s operations (e.g., a consultant hired to prepare emergency/evacuation plans, patient treatment procedures, and patient transfer procedures).
      • CMS clarified that this does not include the mere use of templates. Thus, an SNF that merely purchases template policies from a company would not need to disclose the company as an ADP unless the company is also offering advising, implementation, customization, or any other aspect of the policy development and execution.

    Operational and Management Services

    • Administrative Services: Includes compliance/oversight; nurse staffing companies; human resources; public relations, outreach, and advertising; and technical assistance to the SNF’s main information system.
    • Operational Control and Management Services: Overseeing or having responsibility for any aspect of the SNF’s daily activities or transactions, such as (1) medical records, (2) patient activities, (3) dietary/food operations, (4) maintenance, (5) marketing, (6) social services, and (7) therapy, whether provided under contract or other arrangement with the SNF.
    • Managerial Control: Supervisors and non-supervisors who oversee and are responsible for any aspect of the SNF’s operations, including management and oversight of matters such as maintenance. This does not mean every SNF employee who is responsible for any action in the SNF’s organization (e.g., nurses and administrative assistants) need to be reported. There must be some degree of broader oversight and decision-making authority involved.

    Real Estate

    • Landlords: Leasing or subleasing real property to the SNF.
    • Ownership: Owning a whole or part interest equal to or exceeding 5% of the total value of the SNF’s real property.

    In its guidance, CMS provided a limited list of individuals and entities that are not considered ADPs:

    • Pharmacies, laboratories, and x-ray suppliers.
    • Dietary, custodial, housekeeping, laundry, and building security providers.
    • Government entities, such as state survey agencies, or accrediting organizations.
    • Electronic health record vendors and payroll vendors.
    • Lawyers furnishing legal services so long as their services are within the scope of their lawyer-client relationship and their scope of practice. A lawyer who otherwise exercises managerial control or provides nonlegal services that fall into a category above must be disclosed.

    CMS has instructed SNFs to err on the side of disclosure:

    If the SNF is uncertain as to whether a certain party must be reported, it should disclose said party. As we stated in the November 17, 2023, final rule: “In general, this rule should be construed towards disclosure and, if in doubt about whether additional information should be released, SNFs should disclose it.”

    What Information Must SNFs Disclose on ADPs?

    SNFs must disclose fairly detailed information about ADPs, the services they provide, their organizational structures, and any shared ownership between the ADP and SNF. All required information is detailed in the SNF Attachment. SNFs must obtain the following information from their ADPs:

    • For ADPs that are corporations: All directors and officers and any person or entity with 5% or greater direct or indirect ownership in the corporation.
    • For ADPs that are LLCs: Any person or entity that manages the LLC and any person or entity with a direct or indirect ownership interest in the LLC regardless of ownership percentage.
    • For ADPs that are general partnerships: All persons or entities with a partnership/ownership interest regardless of the percentage.
    • For ADPs that are limited partnerships: All persons or entities with a general partnership/ownership interest (regardless of the percentage) and all persons or entities with a limited partnership interest of at least 10% interest.
    • For ADPs that are trusts: All trustees.

    The SNF must also submit a diagram of the organizational structure of each ADP, which must include a written description of the relationship of each ADP to both the SNF and to all the SNF’s other ADPs. For instance, if the SNF’s management company has an ownership interest in the SNF’s landlord, such relationship must be disclosed.

    What if SNFs Cannot Obtain ADP Information?

    CMS acknowledges that SNFs may have difficulty obtaining information from ADPs but nonetheless requires SNFs to use the “maximum feasible efforts to secure the required data.” However, SNFs are not required to make multiple attempts to obtain information regarding an ADP or its ownership structure if the ADP refuses to provide the data and the information is not available publicly or within the SNF’s records. If a SNF must submit the SNF Attachment to its Medicare administrative contractor (MAC) with missing ADP data, the SNF should include a brief email or letter to the MAC that identifies the missing data. However, CMS stresses that this notification “does not mean or imply that the SNF will automatically be exempt from disclosing this data.” CMS further recommends (though does not require) that the SNF thoroughly document all efforts to obtain data, including the following:

    • Identifying the unattainable data in question
    • Outlining contact attempts (via phone, email, or other means)
    • Identifying the ADP(s) and their reason(s) for refusing to provide data
    • The number of attempts made to obtain the data
    • Whether (and to what extent) the SNF attempted to secure the data via other means if the SNF could not obtain it from the ADP
    • Why all efforts to secure the data have been exhausted, including, but not limited to, why the SNF does not plan to make any additional efforts.

    April 9 Update

    The guidance document was recently updated to provide that companies that furnish physical therapy, occupational therapy, speech-language therapy, or other rehabilitation services to the SNF’s patients are considered ADPs under the “administrative services” category.

    Takeaways

    All SNFs must complete and submit the SNF Attachment by August 1, 2025. The SNF Attachment requires significant information from contractors and service providers who may not be familiar with Medicare disclosure requirements. SNFs should anticipate working closely with ADPs to secure the required information in accordance with CMS guidance. CMS recommends that SNFs work with legal counsel or their professional advisors to determine what information should be disclosed. Certain disclosed data will be publicly available on data.gov in accordance with Privacy Act protections and exceptions for personally identifiable information.

    SNFs must certify that the information they provide CMS is true and accurate, and CMS can take administrative action against SNFs that provide misleading or false information. SNFs that fail to provide ADP disclosures may be subject to administrative penalties from CMS, which can include the denial or revocation of their Medicare enrollment. It remains to be seen how CMS and the MACs will enforce the ADP requirements, particularly in cases where SNFs cannot obtain required information or in cases where ADPs provide SNFs with incorrect information.

    Authors

    Monica Wallace

    Partner

    Chicago

    Evelyn S. Atwater

    Associate

    Chicago

    More insights

  • Private Matters Stay Private: Virginia Strengthens Reproductive Health Data Protections With a Private Right of Action

    Private Matters Stay Private: Virginia Strengthens Reproductive Health Data Protections With a Private Right of Action

    ARTICLE / CLIENT ALERT

    Private Matters Stay Private: Virginia Strengthens Reproductive Health Data Protections With a Private Right of Action

    April 11, 2025

    Read time: 4 min

    Key takeaways
    Overview

    On March 24, 2025, the governor of Virginia signed into law Senate Bill 754, which amends the Virginia Consumer Protection Act (VCPA) to restrict the collection, use, sale, or sharing of personally identifiable reproductive or sexual health information.

    The law has a broad definition of “reproductive or sexual health information” and will impact many companies operating in health- or wellness-related industries. Violations of the law will be enforceable under the VCPA’s private right of action, in addition to being enforceable by the state’s attorney general, so companies should act quickly to ensure compliance before the law becomes effective on July 1, 2025.

    In depth

    Data in Scope

    As amended, the VCPA now prohibits “obtaining, disclosing, selling, or disseminating any personally identifiable reproductive or sexual health information without the consent of the consumer.” “Reproductive or sexual health information” is defined as information relating to the past, present, or future reproductive or sexual health of an individual, and includes:

    • Reproductive or sexual health conditions or status (including pregnancy, menstruation, and whether an individual is sexually active) and symptoms relating to such conditions or status
    • Efforts to obtain reproductive or sexual health information services, including location information that may indicate such efforts
    • Information about treatment or medication relating to reproductive or sexual health conditions, including contraceptives and birth control
    • Information that is derived or extrapolated from non-health-related information, which mirrors consumer health privacy laws such as the Washington My Health My Data Act and brings in scope information that might not commonly be considered health information

    The definition excludes data subject to the federal Health Insurance Portability and Accountability Act, health records under Virginia Code Title 32.1, and records related to substance use disorders that are protected under 42 U.S.C. § 290dd-2.

    Consent Standard

    The law borrows the definition of “consent” from the Virginia Consumer Data Protection Act, meaning that consent must be specific, informed, and affirmative (i.e., opt in). Pre-checked boxes, implied consent, browsewrap agreements, and bundled consent will not be sufficient.

    Enforcement

    Violations of the VCPA are enforceable by Virginia’s attorney general and through a private right of action. The private right of action is available to individuals who suffer loss as a result of a violation and carries statutory damages of $500 for general violations and $1,000 for willful violations.

    Impact

    Based on the broad definition of “reproductive or sexual health information,” the law may impact a wide range of companies that provide health and wellness products. For example, information regarding sexual health and menstruation could include diagnoses and treatments for polycystic ovarian syndrome or a patient’s over-the-counter purchase of pain relief for menstrual cramps. Certain gender-affirming care procedures also inarguably have at least a temporary effect on a patient’s fertility and, therefore, pertain to that patient’s reproductive health. Healthcare companies and providers may wish to revise their patient consent forms for any disclosures related directly or indirectly to reproductive or sexual health information – at least until clarifying regulatory or subregulatory guidance is issued. However, that same consent may be impracticable for application developers and wellness products.

    Companies will need to pay particular attention to their use of online tracking technologies, such as cookies, pixels, and software development kits. These technologies may collect information subject to the law, such as website history data for patients seeking OB/GYN or abortion provider services. With the plaintiff’s bar already trained on tracking technologies, this law will likely generate even more cookie-related litigation.

    What Comes Next?

    Companies operating in Virginia should assess their data practices and consent management procedures to ensure compliance and avoid the risk of private litigation or regulatory enforcement. Please reach out to your regular McDermott lawyer or contact the authors if you have questions or need assistance with preparing for the law.

    Authors

    Jonathan Ende

    Partner

    Washington, DC

    Heidi M. Hutchins

    Associate

    Washington, DC

    More insights

  • When Is a Trade Secret Accessible? As Soon as It Can Be Reverse Engineered

    When Is a Trade Secret Accessible? As Soon as It Can Be Reverse Engineered

    ARTICLE

    When Is a Trade Secret Accessible? As Soon as It Can Be Reverse Engineered

    Apr 10, 2025

    Read time: 4 min

    Key takeaways
    Overview
    In depth

    Although the US Court of Appeals for the Federal Circuit upheld a damages award for trade secret misappropriation and breach of a confidentiality agreement, it found that the district court erred in its determination of when the trade secret became publicly accessible for the purpose of applying a reverse engineering defense. The Federal Circuit also vacated and remanded the prejudgment interest award, finding that interest should not accrue on future sales. ams-OSRAM USA Inc. v. Renesas Elect. America, Inc., Case No. 22-2185 (Fed. Cir. Apr. 4, 2025) (Taranto, Schall, Chen, JJ.)

    In 2008 ams sued Renesas for patent infringement, trade secret misappropriation, and breach of contract for using information that ams revealed in confidence. In 2015 a jury found for ams, and the district court entered judgment for trade secret misappropriation damages, but not for breach of contract. The district court determined that the breach award was duplicative of the misappropriation award. On appeal, in 2018 the Federal Circuit affirmed Renesas’ liability for misappropriation on a more limited basis than had been presented to the jury. The Court vacated the misappropriation award and remanded, instructing that disgorgement of profits damages should be decided by the judge, not the jury.

    On remand, ams argued that it was entitled to “re-elect its remedy” and narrowed to the misappropriation and contract claims, which required the case to be retried. The new jury also found in favor of ams. The district judge then determined the monetary award for trade secret misappropriation, consisting of disgorgement of profits for one product and exemplary damages of double that sum. On ams’s breach of contract claim, the jury awarded a reasonable royalty on sales of products, other than the one subject to disgorgement damages. ams was also awarded prejudgment interest on both its misappropriation and contract claims, and attorneys’ fees on its breach of contract claim. Both parties appealed.

    Trade Secret Accessibility and Reverse Engineering

    The district court ruled that ams’s trade secrets became accessible in January 2006 when Renesas successfully reverse engineered the trade secret embodied in ams’s product. The district court determined that the relevant inquiry for accessibility is what the misappropriator actually did rather than what the misappropriator or other parties could have done. Renesas argued that the trade secret first became accessible when it could have reverse engineered the trade secret in February 2005.

    The Federal Circuit agreed with Renesas, explaining that the district court’s ruling was inconsistent with Texas law. Under Texas law, information that is generally known or readily available by independent investigation does not qualify as a trade secret. Citing Fifth Circuit precedent, the Federal Circuit emphasized that the public is free to discover and exploit trade secrets through reverse engineering of products in the public domain. The Court found that Renesas could have accessed ams’s trade secrets through proper and straightforward means by February 2005. While acknowledging that the trade secret may not have been immediately apparent through casual inspection, the Court pointed out that reverse engineering is a common and widespread practice within the industry and could have been completed within approximately one week.

    Prejudgment Interest

    Renesas argued that the district court erred in awarding prejudgment interest on the entire damages amount from the date the complaint was filed, including future sales. Renesas contended that a portion of the sales for which disgorgement (trade secret) or reasonable royalty (breach) awards were made occurred after the complaint was filed, and thus ams “could not have been entitled to disgorged profits or a reasonable royalty for sales that had not yet occurred.”

    Applying California law to the contract claim and Texas law to the trade secret claim, the Federal Circuit found that interest cannot accrue on a recovery-triggering event until that event has actually occurred. While the district court has discretion to award prejudgment interest, it cannot allow interest to accrue before the actual loss-causing event (product sales), because no right to recover damages vests until then. The Court remanded the case for recalculation of prejudgment interest, ensuring that interest is applied only to sales that actually occurred.

    Authors

    Jodi Benassi

    Partner

    San Francisco

    More insights
    Endnotes

  • The Employee Retention Credit: How to Litigate and Resolve Claims

    The Employee Retention Credit: How to Litigate and Resolve Claims

    ARTICLE

    The Employee Retention Credit: How to Litigate and Resolve Claims

    Apr 10, 2025

    Read time: 2 min

    The Employee Retention Credit (ERC) was designed to help employers keep their employees on payroll during the COVID-19 pandemic by offering a refundable tax credit against certain employment taxes. Despite the Internal Revenue Service (IRS) issuing more than $242 billion in ERC as of early 2025, the processing and payment of these claims have faced significant delays and scrutiny.

    In a recent Bloomberg Tax article, McDermott’s tax controversy and litigation team shared a broad overview of the stages of ERC claims and potential ways in which taxpayers can resolve them. Key takeaways include:

    • ERC claims can be in one of four stages: no IRS action, IRS examination, formal disallowance, or IRS recapture. Understanding the implications of each stage can be crucial for maximizing taxpayers’ chances of receiving and keeping ERC.
    • Thousands of ERC claims remain stagnated in the IRS’s administrative review process. Litigation can be a powerful tool to expedite the payment of ERC claims.
    • Taxpayers must be highly vigilant about the applicable statutes of limitations concerning ERC refund claims. Not understanding these deadlines can undermine the potential for a successful ERC claim.
    • The IRS is capable of recapturing ERC that it believes was erroneously allowed. However, the mechanisms for recapture may be susceptible to legal challenge, and taxpayers should be aware of their litigation options.

    Read the full article.

    In depth
    Authors

    Shawn O'Brien

    Partner

    Houston

    Michael J. Scarduzio

    Partner

    New York – One Vanderbilt Avenue

    Samuel F. Hamer

    Associate

    Washington, DC

    More insights
    Endnotes

  • Heard at the 2025 Antitrust Law Section Spring Meeting

    Heard at the 2025 Antitrust Law Section Spring Meeting

    ARTICLE / US POLICY

    Heard at the 2025 Antitrust Law Section Spring Meeting

    April 7, 2025

    Read time: 11 min

    Key takeaways
    Overview

    The American Bar Association Antitrust Law Section’s annual Spring Meeting took place from April 2 to 5 in Washington, DC. The Spring Meeting features updates from federal, state, and international antitrust enforcers and extensive discussion of antitrust issues and enforcement priorities affecting various industries. This year, key leaders of the antitrust agencies spoke about antitrust enforcement at a concurrent program hosted by The Capitol Forum/FGS Global.

    This client alert highlights key takeaways from the Spring Meeting and the Capitol Forum/FGS Global program.

    In depth

    Antitrust Enforcement Under the Trump Administration

    • Federal Trade Commission (FTC) cases brought against Big Tech platforms are likely to continue under the Trump administration, although the reasons for continuing such cases and the alleged harms may shift. Former FTC Chair and Commissioner Maureen Ohlhausen emphasized that the new FTC majority may continue to focus on such cases due to the alleged harm that concentration in Big Tech has caused, such as reduced viewpoint diversity and suppression of conservative speech. Ohlhausen’s remarks align with comments made by new FTC and US Department of Justice (DOJ) leadership about increasing antitrust scrutiny on Big Tech.
    • There are concerns about the rule of law and respect for the courts. The dismissal of the FTC’s two Democratic Commissioners, Rebecca Slaughter and Alvaro Bedoya, raised serious concerns at the Spring Meeting regarding the immediate and downstream effects of the potential overturn of Humphrey’s Executor, a landmark Supreme Court decision that established limits on the president’s power to remove officials from independent regulatory agencies like the FTC. If federal agencies are no longer seen as insulated from the political will of a president, they may lose the persuasiveness and deference they receive in court and from Americans nationwide. However, the FTC is not without political oversight in its current form, as it is subject to the authority of Congress, which controls its jurisdiction and existence. Despite this, panelists unanimously embraced the importance of the consensus-building nature of a bipartisan Commission.
    • Antitrust enforcers expect a shift in attitude towards mergers. During the Capitol Forum/FGS Global program, FTC Chair Ferguson said he does not share the prior administration’s predisposition against mergers and believes long merger reviews under the prior administration led to uncertainty. He noted that the FTC retained the 2023 Merger Guidelines adopted under Biden to provide more certainty and clarity for the business community and to avoid politicizing the guidelines. The FTC will continue to scrutinize mergers, but according to Ferguson, the FTC will “get out of the way” more quickly for deals that do not harm competition.
    • Section 2 Sherman Act enforcement is likely to persist. Many ongoing Section 2 cases are expected to keep the FTC and DOJ busy in the coming years. FTC Chair Ferguson is likely to increase the use of Section 2 in cases concerning alleged filtering of speech by Big Tech companies. However, the DOJ is unlikely to devote significant resources to criminal enforcement of Section 2.
    • Robinson-Patman Act (RPA) enforcement is likely to continue at a steady pace. Panelists highlighted that Mark Meador, President Trump’s FTC commissioner nominee, has publicly stated that not enforcing the RPA at all “offends the rule of law.” Therefore, companies should not count on fewer RPA enforcement actions under the Trump administration. Similarly, in a dissenting statement from a recent enforcement action, FTC Chair Ferguson stated that the FTC “should focus its enforcement efforts on price discrimination in the heartland of the concern that animated the Act’s passage—large retailers with buying power.”

    Antitrust Agencies’ Priorities and Focus

    Merger Review and Remedies

    • Agencies under the Trump administration are more likely to enter settlements and entertain fixes. At the Capitol Forum/FGS Global program, Assistant Attorney General Gail Slater, head of the DOJ’s Antitrust Division, said she wants to bring back merger remedies, especially structural remedies such as divestitures. FTC Chair Ferguson also noted that the government’s resources are limited, and he believes realistic remedies protect consumers, while refusing to engage with merging parties on remedies does not help consumers. In determining when to offer a fix, merging parties should consider the benefits of offering a remedy early to build credibility with enforcers and the court, prevent allegations of sandbagging, and maintain a consistent perspective on their proposed fix throughout the investigation. Roger Alford, a senior US DOJ official, highlighted the importance of “try[ing] to make [deals] as clean as possible” and noted that if the agencies can “fix a few pieces” to a merger, it allows the agency to move forward efficiently with a consent decree rather than engage in costly and protracted litigation.
    • Non-price parameters weigh heavily in merger review. When evaluating a transaction, the antitrust agencies evaluate non-price parameters with equal attention and scrutiny as price-related aspects. Non-price parameters highlighted by the FTC, as well as enforcers from the European Commission, during the Spring Meeting included factors such as innovation, product features, product design, product quality, product safety, sustainability, better carbon emissions, labor, store conditions, and store experience, among others. The agencies made clear that innovation is not a defense to an anticompetitive transaction; they will conduct a balancing exercise between the anticompetitive harm and the benefits of the innovation. The FTC’s leaders disagreed with the assertion that non-price parameters are a mechanism to block a deal they oppose and explained that they merely follow the facts of the case and talk to customers and competitors to understand multiple facets of the industry.
    • Healthcare mergers will receive continued and heightened scrutiny. Efficiencies arguments from merging parities in the healthcare industry are subject to scrutiny from regulators, who question whether mergers are the best method for achieving value-based care, even in cases of flailing firms. Commercial realities, including non-price concerns such as the impact on patient access and quality of care, are very important to regulators when reviewing healthcare mergers. State attorneys general indicated reliance on the involvement of several other state agencies and other sets of laws to regulate healthcare issues, such as offices of healthcare affordability to examine price issues, departments of insurance to understand the interplay of health providers and insurance companies, and even charitable trust laws to examine the transactions of nonprofit entities.
    • Merger trials require fact-intensive efforts. When litigating antitrust agency challenges to mergers, it is important to make antitrust accessible to a district court judge who may not be as familiar with the practice. Judges urge practitioners to show their work – define all facts and arguments in detail and consider providing a glossary of straightforward definitions for antitrust terms, as well as terms related to the industry in which the merger is occurring. Judges also encourage practitioners to bridge the gaps in knowledge with use of expert witnesses. While experts know their field well, they can struggle to explain issues clearly to a judge. Therefore, practitioners should consider facilitating an informal conversation between the experts and the presiding judge to answer any questions and provide detailed executive summaries of expert reports using language appropriate for laypersons. In courts where antitrust case law is older, judges must work harder to figure out not only whether a transaction is anticompetitive but also what the appropriate standard of review is and where to draw the line. Judges highlighted that arguments in merger trials are most persuasive when parties recognize their weaknesses but still make a strong case for why their side should prevail.

    State Enforcers Remain Active

    • State attorneys general will continue to push the boundaries of the antitrust laws regardless of a change in the administration. Multiple state enforcers emphasized that they are unafraid to pursue antitrust actions even without the federal government. For example, state attorneys general are seeking to develop their state antitrust laws by bringing cases in state court. This is the case for states like New York, which has state antitrust laws based on federal antitrust laws, as well as states like Ohio and Texas, which have state antitrust laws that are not analogous to federal antitrust laws. State enforcers noted that bringing cases is often as important as winning them. Winning means protecting their citizens’ interests, while losing can identify a need for statutory change. States are frequently hiring outside counsel to assist with investigations and litigation.
    • States to step in if federal merger enforcement subsides. Regarding the future of merger enforcement, Colorado Attorney General Phil Weiser emphasized that the states are ready to fill any gaps in federal enforcement, citing Colorado’s challenges (both jointly with federal agencies and independently) to many prominent mergers as evidence of the states’ capability and focus on antitrust. Elizabeth Odette, Minnesota’s assistant attorney general for antitrust  and chair of the National Association of Attorneys General’s Antitrust Task Force, said parties should not overlook state enforcers and noted that state enforcers across the country are increasing their antitrust enforcement capabilities.
    • Federal enforcement agencies may defer to state enforcers when the conduct is of a local nature. However, states may also, on their own, bring cases that are within the traditional purview of the federal enforcers. For example, the Colorado attorney general sued separately in state court to block a merger between two large national grocery retailers. Suing separately allows the state attorneys general to bring other claims not addressed by federal enforcers (e.g., an alleged no-poach agreement in the grocery retailer merger).
    • An increase in civil cases and a decrease in criminal cases is generally expected. Due to the significant decline in DOJ criminal antitrust enforcement, states with robust antitrust enforcement programs, like California and New York, plan to continue bringing cases focused on bid rigging and price-fixing. However, most states do not have the resources or leniency programs to investigate national cartels.

    Noncompetes

    • The future of the FTC noncompete rule is uncertain. FTC Chair Ferguson believes the FTC should reconsider its defense of the FTC’s April 2024 noncompete rule, which, per an August 2024 court order, cannot be enforced and remains subject to appeal. The rule would have banned existing and new noncompete agreements between employers and employees. The FTC claims the noncompete ban would lead to more innovation, more startups, and higher earnings for American workers. If the FTC abandons its defense of the rule, other groups, such as the Small Business Majority, may move to intervene to continue the fight on appeal. If the rule is eventually found to be unlawful on appeal, however, there are still many states – such as California, Minnesota, and New York – that already have laws or are actively working on legislative efforts to prohibit noncompetes, with which employers will still need to comply.
    • Despite his dissent, FTC Chair Ferguson still sees value in enforcing unlawful noncompetes. Chair Ferguson noted that while he dissented from the FTC’s noncompete rule banning employee noncompetes, he does plan to vigorously enforce unlawful noncompetes. He observed that the traditional “rule of reason” approach can distinguish between noncompetes that have benefits and those that harm competition. Ferguson believes this is an opportunity to protect American workers.

    Consumer Protection

    • Price transparency is at the center of consumer protection enforcement. With recent FTC rulemaking and priorities, the Commission is focusing on enforcing hidden and junk fees, advertisements for free goods or services, and bait-and-switch practices. Last week, the Trump administration strongly endorsed the new junk fees rule by issuing an executive order relating to price transparency throughout all stages of purchasing a ticket to promote competition law enforcement  and better protect fans from exploitative ticket scalping.
    • Deceptive and misleading influencer product endorsement and consumer reviews remain a high priority for enforcement. Following the 2023 updates to the FTC’s Endorsement Guides, the Commission issued an explicit ban on fake reviews. State enforcers are also cracking down on fake consumer reviews. If an individual advertises a product or leaves a review of a product, they must be an authentic user of the product. If someone portrays themselves as an expert, they must have a special kind of expertise to be able to comment on certain products or services. Additionally, a recent National Advertising Division decision held that a product demonstration constitutes an endorsement. If there is a material connection (i.e., the advertiser received free product, was paid, or has some other connection to the brand), the endorser posting the advertising content must include a disclosure indicating as such.
    • The Trump administration will take a different approach to consumer protection but remain active  in enforcement. FTC Chair Ferguson is very dedicated to the consumer protection agenda of the Commission, although we are likely to see more enforcement action and less rulemaking or rule-driven activity. Enforcement of consumer protection issues at the state level is also expected to increase.
    Authors

    Lisa P. Rumin

    Partner

    Washington, DC

    Anthony S. Ferrara

    Partner

    Washington, DC

    Megan C. Ingram

    Associate

    Washington, DC

    Royce E. Brosseau

    Associate

    Washington, DC

    Claire E. Danberg

    Associate

    Washington, DC

    Betty (Yajing) Zhang

    Associate

    Los Angeles

    More insights

  • EEOC Issues Guidance on DEI-Related Discrimination at Work

    EEOC Issues Guidance on DEI-Related Discrimination at Work

    ARTICLE / CLIENT ALERT

    EEOC Issues Guidance on DEI-Related Discrimination at Work

    April 4, 2025

    Read time: 5 min

    Key takeaways
    Overview

    On March 19, 2025, the US Equal Employment Opportunity Commission (“EEOC”) released two documents to inform employers and employees how civil rights laws apply to diversity, equity, and inclusion (“DEI”) policies, programs and practices in the workplace.

    A one-page technical assistance document, “What to Do If You Experience Discrimination Related to DEI at Work,” provides basic information on recognizing and addressing DEI-related discrimination. It notes “DEI policies, programs, or practices may be unlawful if they involve an employer or other covered entity taking an employment action motivated—in whole or in part—by an employee’s race, sex, or another protected characteristic.” A more detailed question-and-answer technical assistance document, “What You Should Know About DEI-Related Discrimination at Work,” serves as a roadmap on how the EEOC will apply Title VII of the Civil Rights Act of 1964 (“Title VII”) to DEI initiatives and outlines the process for filing charges of discrimination with the EEOC. It emphasizes that Title VII does not only apply to individuals who are part of a “minority group,” but applies equally to all workers. The EEOC’s position is that “there is no such thing as ‘reverse’ discrimination; there is only discrimination.”

    The release of these documents underscores the federal government’s growing scrutiny of DEI initiatives. In particular, the question-and-answer document highlights potential legal pitfalls for employers when implementing or managing DEI programs.

    EEOC’s Guidance in its Question-and-Answer Document

    In this technical assistance document, the EEOC clarifies when DEI initiatives may cross the line into unlawful discrimination under Title VII. The guidance explains that Title VII prohibits employment decisions based on race, sex or other protected characteristics — even if DEI programs are aimed at promoting diversity.

    The responses to Question 7 explain that DEI initiatives may be unlawful if they involve employment actions motivated by “protected characteristics” under Title VII, such as race or sex. Employers are prohibited from “limiting, segregating, or classifying employees or applicants based on race, sex, or other protected characteristics” in any manner which affects their status or deprives them of employment opportunities. For example, it would be unlawful to limit membership in employer-sponsored activities for employees such as clubs or groups, including limiting membership in workplace groups, such as Employee Resource Groups (“ERGs”) or other employee affinity groups.

    Further, separating employees by their protected characteristics during DEI or other workplace trainings is prohibited, even if the groups receive the same content or resources. Employers also cannot restrict or grant access to mentorship, sponsorship, internship, fellowship or networking programs, including skill-building or leadership development programs, based on these protected traits. “Employers also should ensure that employees of all backgrounds … have equal access to workplace networks.”

    The responses to Questions 10 and 11 warn that DEI training could create a hostile work environment and/or give rise to claims of harassment. The EEOC highlights court cases in which employees successfully alleged that DEI-related training was discriminatory. For example, the EEOC notes that courts have ruled in favor of plaintiffs who provided evidence that DEI programs were discriminatory “in content, application, or context.” The technical assistance documents reference that “opposition to a DEI training may constitute protected activity if the employee provides a fact-specific basis for his or her belief that the training violates Title VII.”

    Next Steps for Employers

    In light of these recent developments, all employers should evaluate their current DEI-related policies, practices and programs by conducting legally-privileged audits and risk assessments to ensure compliance with existing anti-discrimination statutes, such as Title VII. Any DEI initiative which uses race, gender or similar classification as an eligibility criterion should be particularly analyzed, including those policies, practices and programs related to recruitment, hiring, workplace affinity and culture, and promotion. Employers are still permitted to advertise that they are an equal opportunity employer and do not discriminate on the basis of any applicable legally protected characteristic. Care should be taken as well regarding language used in describing DEI initiatives on websites and in other public disclosures.

    Authored by Mark E. Brossman, Ronald E. Richman, Martin L. Schmelkin, Donna K. Lazarus, Scott A. Gold, and Danisa D. Foote.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2025 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Mark E. Brossman

    Partner

    New York – 919 Third Avenue

    Ronald E. Richman

    Partner

    New York – 919 Third Avenue

    Martin L. Schmelkin

    Partner

    New York – 919 Third Avenue

    Donna K. Lazarus

    Partner

    New York – 919 Third Avenue

    More insights